Tirzapic 60mg/3ml 1 Pen by Pharmacona

Usage

1. Remove the Tirzapic pen from refrigerator storage 30 minutes before injection to allow the solution to reach room temperature — cold solution increases injection-site discomfort and may affect flow rate.
2. Inspect the solution through the pen window: tirzepatide should appear clear to slightly yellow and free of visible particles; discard the pen if the solution is cloudy, discoloured, or contains floating matter.
3. Dial the dose selector to the prescribed weekly dose (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg) as instructed in your titration protocol — confirm the number displayed before attaching the needle.
4. Select an injection site — abdomen (at least 5 cm from the navel), upper thigh, or outer upper arm — and rotate sites weekly to prevent lipohypertrophy, a consideration relevant across all prefilled-pen incretin formats regardless of receptor profile.
5. Insert the pen needle at a 90-degree angle, press the injection button fully, and hold for a full 10 seconds before withdrawing to ensure complete dose delivery from the pen's 3 ml reservoir.
6. After injection, cap the needle for safe disposal, record the date and dose administered, and store the open pen at room temperature (≤30 °C) for no more than 21 days — discard any remaining solution beyond this window irrespective of fill level.

Warnings

Frequently asked questions

How does tirzepatide compare to semaglutide in terms of weight loss outcomes?

Clinical data position tirzepatide above semaglutide for mean percentage body-weight reduction: SURMOUNT-1 reported approximately 20.9 % weight loss at the 15 mg tirzepatide dose over 72 weeks, while semaglutide 2.4 mg across STEP trials delivered approximately 14–15 %. The additional GIP receptor engagement in tirzepatide — absent in semaglutide — is the primary mechanistic explanation for this measurable difference in efficacy.

What receptor does tirzepatide activate that semaglutide does not?

Tirzepatide activates the glucose-dependent insulinotropic polypeptide (GIP) receptor in addition to the GLP-1 receptor that semaglutide targets exclusively. GIP receptor co-activation enhances peripheral insulin sensitivity and contributes to the incremental metabolic effect observed when tirzepatide and semaglutide outcomes are compared head-to-head in indirect analyses of their respective Phase 3 datasets.

Is tirzepatide stronger than retatrutide for fat loss?

Current Phase 2 data suggest retatrutide's triple-receptor mechanism — adding glucagon receptor agonism to the GLP-1/GIP combination already present in tirzepatide — produces higher mean weight loss (approximately 24 % at 48 weeks versus tirzepatide's approximately 20.9 % at 72 weeks in Phase 3). However, tirzepatide carries a larger and more mature long-term safety dataset, making it the more evidence-supported choice before progressing to triple-receptor compounds.

How does the 60mg/3ml concentration of Tirzapic compare to lower-concentration tirzepatide pens?

At 60 mg per 3 ml, Pharmacona's Tirzapic is the highest-concentration tirzepatide prefilled pen in the current Pharmacona range. This format accommodates the full recommended titration sequence — from a 2.5 mg starting dose through a 15 mg maintenance dose — within a single pen, removing the need for mid-cycle pen changes and reducing per-dose cost relative to lower-concentration alternatives.

How should the Tirzapic prefilled pen be stored and used after first injection?

Store Tirzapic pens refrigerated at 2–8 °C before first use; opened pens may be kept at room temperature (up to 30 °C) for a maximum of 21 days. Tirzepatide is administered as a once-weekly subcutaneous injection into the abdomen, thigh, or upper arm, using the pen's integrated dial-dosing mechanism to set the prescribed dose. Discard any pen that has been open beyond 21 days regardless of remaining volume. (2) angle_used

Manufacturer

Pharmacona's Tirzapic sits within the company's prefilled-pen injectable peptide line — a product category distinct from its solid oral dosage unit portfolio — and represents the tirzepatide entry in a range that spans multiple active incretin-class compounds including semaglutide-based and retatrutide-based pens. The 60 mg/3 ml fill specification for Tirzapic reflects a deliberate formulation decision: it is the highest tirzepatide concentration currently offered within the Pharmacona pen portfolio, engineered to support uninterrupted dose titration across a full clinical protocol without requiring pen replacement. Batch release for Tirzapic is governed by Pharmacona's injectable-grade quality framework; each lot must clear two mandatory release criteria — HPLC (High-Performance Liquid Chromatography) active-ingredient quantification confirming the declared 60 mg tirzepatide per pen, and LAL (Limulus Amebocyte Lysate) endotoxin testing establishing compliance with parenteral safety thresholds — before any unit is released from the GMP-certified production environment. Certificates of Analysis are available to verified purchasers at the batch level.